Full Press Release Details
PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs.
BBIO
PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs
Key Takeaway: PellePharm Presents Updated Data From Two Phase 2 Studies Demonstrating The Potential Of Patidegib Topical Gel To Treat Basal Cell Carcinomas In Patients With Gorlin Syndrome And Patients With Non-Gorlin Sporadic BCCs